argenx to Present at 39th Annual J.P. Morgan Healthcare Conference
04 Janeiro 2021 - 3:00AM
January 4, 2021 Breda,
the Netherlands / Ghent, Belgium – argenx (Euronext &
Nasdaq: ARGX), a global immunology company committed to improving
the lives of people suffering from severe autoimmune diseases and
cancer, today announced that Tim Van Hauwermeiren, Chief Executive
Officer, will present at the 39th Annual J.P. Morgan Healthcare
Conference on Monday, January 11, 2021 at 8:20 a.m. ET.
A live webcast of the presentation will be
available on the Company’s website at www.argenx.com. A replay of
the webcast will be available for 90 days following the
presentation.
About argenxargenx is a global
immunology company committed to improving the lives of people
suffering from severe autoimmune diseases and cancer. Partnering
with leading academic researchers through its Immunology Innovation
Program (IIP), argenx aims to translate immunology breakthroughs
into a world-class portfolio of novel antibody-based medicines.
argenx is evaluating efgartigimod in multiple serious autoimmune
diseases, and cusatuzumab in hematological cancers in collaboration
with Janssen. argenx is also advancing several earlier stage
experimental medicines within its therapeutic franchises. argenx
has offices in Belgium, the United States, and Japan. For more
information, visit www.argenx.com and follow us on LinkedIn.
For further information, please contact:
Beth DelGiacco, Vice President, Corporate Communications &
Investor Relations +1 518 424 4980bdelgiacco@argenx.com
Joke Comijn, Director Corporate Communications & Investor
Relations (EU)+32 (0)477 77 29 44+32 (0)9 310 34
19jcomijn@argenx.com
Argen X (EU:ARGX)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Argen X (EU:ARGX)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
